https://www.indianpharmapost.com/usfda-concludes-inspection-at-solaras-cuddalore-facility-with-zero-483-inspectional-observations-144912023-08-08T00:00:00+05:30always0.9https://www.indianpharmapost.com/kims-posts-q1-fy24-consolidated-pat-at-rs-8081-cr-144922023-08-08T00:00:00+05:30always0.9https://www.indianpharmapost.com/torrent-pharmaceuticals-posts-q1-fy-24-consolidated-pat-at-rs-378-cr-144932023-08-08T00:00:00+05:30always0.9https://www.indianpharmapost.com/gland-pharma-posts-q1-fy24-consolidated-pat-at-rs-19410-cr-144942023-08-08T00:00:00+05:30always0.9https://www.indianpharmapost.com/surging-demand-for-korean-pharma-in-2023-ahead-of-cphi-korea-144952023-08-08T00:00:00+05:30always0.9